Overview

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Status:
Recruiting

Trial end date:
2026-03-17

Target enrollment:

Participant gender:

Summary

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Collaborators:

Genentech, Inc; Onyx Therapeutics, Inc.
Genentech, Inc.
Onyx Therapeutics, Inc.

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Venetoclax